Hypersensitivity Reactions to Gadolinium‐Based Contrast Agents: Update From an Allergist's Point of View

TL;DR

This paper reviews hypersensitivity reactions to MRI contrast agents and provides updated allergological strategies for diagnosis and management.

Contribution

The paper offers updated allergological insights and management strategies for hypersensitivity reactions to gadolinium-based contrast agents.

Findings

Adverse events to GBCAs are classified into Type A and Type B reactions, with Type B being dose-independent hypersensitivity reactions.

Allergological evaluation, including skin testing and graded challenges, is critical for safe re-exposure in patients with prior reactions.

Abstract

The increasing use of Magnetic Resonance Imaging (MRI) has led to a rise in the administration of gadolinium‐based contrast agents (GBCAs), accompanied by a growing number of reported adverse events (AEs).

This review aims to provide an updated overview of hypersensitivity reactions (HSRs) to GBCAs, focusing on diagnostic and management strategies from an allergological perspective.

We reviewed recent literature concerning the classification, clinical presentation, and pathophysiological mechanisms of HSRs to GBCAs. Particular attention was given to current recommendations for diagnosis, risk stratification, and prevention.

Adverse events to GBCAs are categorized into Type A reactions, which are dose‐dependent and predictable, and Type B reactions, which are dose‐independent hypersensitivity reactions. The latter may be allergic or non‐allergic, presenting diagnostic and therapeutic challenges.

HSRs to GBCAs, though relatively rare, require careful evaluation and tailored management. An allergological work‐up, including skin testing and graded challenges when appropriate, plays a critical role in the safe re‐exposure of patients with prior reactions.

Figures